▁Anal 8.7265625
yst 1.59375
s 0.73681640625
▁await 7.0
▁new 7.5546875
▁evidence 4.7578125
▁about 4.109375
▁British 7.5390625
▁Bi 10.234375
ote 1.34765625
ch 0.039398193359375
' 2.01171875
s 0.002346038818359375
▁anti 6.6171875
- 0.04296875
can 1.7763671875
cer 0.001567840576171875
▁treatment 3.20703125
▁Mar 10.515625
im 4.69140625
ast 0.0096588134765625
at 9.524822235107422e-05
▁at 4.40625
▁ES 8.125
MO 0.0098876953125
▁meeting 2.474609375
<0x0A> 0.76708984375
<0x0A> 9.3984375
In 4.2265625
vest 0.369384765625
ors 0.1611328125
▁and 2.9765625
▁ph 5.40234375
arma 0.0215301513671875
ce 0.57275390625
ut 8.797645568847656e-05
ical 0.000591278076171875
▁anal 0.4599609375
yst 0.00018680095672607422
s 0.002410888671875
▁are 1.1572265625
▁eager 2.681640625
ly 0.11529541015625
▁await 0.1448974609375
ing 0.0016012191772460938
▁new 1.5380859375
▁clin 2.255859375
ical 0.0006809234619140625
▁trial 1.451171875
▁data 0.77978515625
▁on 1.0078125
▁British 0.99169921875
▁Bi 0.0423583984375
ote 0.0018148422241210938
ch 0.00844573974609375
' 0.363037109375
s 0.0009937286376953125
▁experimental 2.90234375
▁anti 0.716796875
- 0.005184173583984375
can 0.024200439453125
cer 0.0004258155822753906
▁drug 1.1533203125
▁Mar 0.256103515625
im 0.002216339111328125
ast 0.0004470348358154297
at 8.308887481689453e-05
▁at 1.1669921875
▁the 0.492919921875
▁European 0.59130859375
▁Society 0.1640625
▁of 1.9169921875
▁Medical 0.029449462890625
▁On 0.003772735595703125
col 0.0743408203125
ogy 0.00017905235290527344
▁meeting 1.3603515625
▁this 2.95703125
▁week 0.09698486328125
. 0.705078125
▁Mar 3.98828125
im 0.004238128662109375
ast 0.0010004043579101562
at 0.0006852149963378906
▁is 0.78662109375
▁an 2.3515625
▁anti 3.203125
- 0.046112060546875
can 1.5419921875
cer 0.0003769397735595703
▁drug 1.0830078125
▁that 1.0205078125
▁works 2.48828125
▁by 0.265380859375
▁in 1.5244140625
hib 0.0164794921875
iting 0.0030879974365234375
▁en 3.64453125
zym 0.0004954338073730469
es 0.1002197265625
▁involved 2.255859375
▁in 0.01444244384765625
▁tum 2.111328125
or 1.8623046875
▁growth 0.58935546875
▁and 1.4814453125
▁spread 2.330078125
. 0.359130859375
<0x0A> 1.0107421875
<0x0A> 11.171875
In 2.72265625
▁previous 7.02734375
▁clin 1.2666015625
ical 0.0007104873657226562
▁tri 0.088623046875
als 1.6689300537109375e-05
, 0.353271484375
▁Mar 0.410400390625
im 0.002593994140625
ast 0.00034618377685546875
at 0.0012960433959960938
▁has 0.58740234375
▁shown 0.880859375
▁promise 1.9833984375
▁in 0.52197265625
▁extending 5.3828125
▁surv 1.2333984375
ival 0.001949310302734375
▁and 2.318359375
▁slow 2.30859375
ing 0.0019245147705078125
▁tum 1.3134765625
or 0.08953857421875
▁pro 1.98828125
gression 0.0037174224853515625
▁in 0.2509765625
▁patients 0.408203125
▁with 0.05950927734375
▁advanced 0.76123046875
▁pan 2.759765625
cre 0.00016510486602783203
atic 0.0238189697265625
, 2.10546875
▁o 2.4375
var 0.00469207763671875
ian 5.710124969482422e-05
▁and 0.86083984375
▁g 3.294921875
astr 0.361083984375
ic 0.0003292560577392578
▁can 0.7626953125
cers 0.0001112222671508789
. 0.1884765625
▁The 1.775390625
▁new 2.685546875
▁Ph 4.4375
ase 0.0017194747924804688
▁III 0.282470703125
▁trial 0.83056640625
▁results 3.771484375
▁to 3.42578125
▁be 0.003192901611328125
▁presented 0.280029296875
▁this 2.787109375
▁week 0.0108489990234375
▁involve 3.63671875
▁over 4.33984375
▁ 0.0139007568359375
7 2.720703125
0 0.20068359375
0 0.0055084228515625
▁patients 0.1619873046875
▁with 0.279541015625
▁advanced 0.66943359375
▁st 4.375
om 0.00046944618225097656
ach 0.00020241737365722656
▁cancer 0.42919921875
▁who 1.7353515625
▁were 1.06640625
▁given 1.701171875
▁Mar 1.068359375
im 0.002391815185546875
ast 0.0004303455352783203
at 0.0009431838989257812
▁in 1.4462890625
▁combination 0.67529296875
▁with 0.00499725341796875
▁standard 1.7744140625
▁chem 0.202880859375
other 0.0017547607421875
apy 0.01343536376953125
. 0.67626953125
▁Anal 4.4140625
yst 0.0008687973022460938
s 0.01425933837890625
▁expect 2.771484375
▁the 0.71435546875
▁data 1.599609375
▁to 0.09576416015625
▁show 1.1171875
▁at 6.4921875
▁a 6.52734375
▁minimum 0.408935546875
▁an 3.0390625
▁extension 2.52734375
▁of 0.689453125
▁surv 0.61669921875
ival 0.0016908645629882812
▁by 3.595703125
▁several 2.689453125
▁months 0.07916259765625
▁compared 1.8994140625
▁to 0.457763671875
▁chem 1.1845703125
other 0.00923919677734375
apy 0.0003495216369628906
▁alone 0.03448486328125
. 0.2396240234375
▁If 3.1484375
▁the 0.5166015625
▁trial 2.357421875
▁shows 1.873046875
▁more 4.546875
▁substantial 3.611328125
▁benefits 1.4921875
, 0.2783203125
▁it 2.080078125
▁could 0.398681640625
▁position 5.05859375
▁Mar 0.2431640625
im 0.0012769699096679688
ast 9.715557098388672e-05
at 0.0006122589111328125
▁as 0.4365234375
▁a 0.4853515625
▁block 4.05859375
b 0.00557708740234375
uster 0.00099945068359375
▁drug 0.468017578125
▁with 1.9423828125
▁over 3.5625
▁$ 0.288330078125
1 0.38037109375
▁billion 0.192626953125
▁in 0.1275634765625
▁annual 0.64599609375
▁sales 0.0743408203125
. 0.38134765625
▁▁▁▁ 13.796875
<0x0A> 0.1923828125
<0x0A> 0.074462890625
B 2.4140625
rit 0.03472900390625
ish 0.0022487640380859375
▁Bi 0.016632080078125
ote 0.0005345344543457031
ch 0.003387451171875
' 1.537109375
s 0.00036406517028808594
▁share 1.974609375
▁price 0.04254150390625
▁has 0.401611328125
▁already 2.630859375
▁ris 0.99853515625
en 7.772445678710938e-05
▁over 2.3125
▁ 0.031280517578125
3 1.986328125
0 0.2100830078125
% 0.6357421875
▁in 1.07421875
▁the 1.2314453125
▁past 0.7568359375
▁month 1.1123046875
▁in 1.9267578125
▁anticip 0.0582275390625
ation 0.00023436546325683594
▁of 0.006351470947265625
▁positive 3.013671875
▁trial 1.03515625
▁results 0.22607421875
. 0.33203125
▁The 1.33203125
▁company 0.927734375
' 1.1767578125
s 0.0001277923583984375
▁future 5.8515625
▁h 2.93359375
ing 0.0014963150024414062
es 0.00024259090423583984
▁on 0.062255859375
▁the 0.326171875
▁success 0.76025390625
▁of 0.0157012939453125
▁Mar 0.32568359375
im 0.001628875732421875
ast 0.00041747093200683594
at 0.00025463104248046875
, 0.261962890625
▁as 0.80810546875
▁it 0.66748046875
▁represents 8.7734375
▁British 3.291015625
▁Bi 0.004985809326171875
ote 3.6716461181640625e-05
ch 0.0010366439819335938
' 0.005035400390625
s 0.00015425682067871094
▁most 5.13671875
▁advanced 0.307861328125
▁candidate 4.37109375
▁and 0.89794921875
▁the 1.849609375
▁company 1.7021484375
' 0.418212890625
s 0.00018966197967529297
▁only 0.1756591796875
▁drug 2.9453125
▁in 0.42236328125
▁late 0.5986328125
- 0.1480712890625
stage 0.0027561187744140625
▁clin 0.310546875
ical 0.0002028942108154297
▁tri 0.42724609375
als 1.7523765563964844e-05
. 0.007129669189453125
▁While 4.84375
▁anal 2.58203125
yst 0.0001590251922607422
s 0.00514984130859375
▁remain 2.107421875
▁c 1.1943359375
aut 8.749961853027344e-05
iously 0.50439453125
▁optim 0.006534576416015625
istic 0.00023806095123291016
, 1.84765625
▁disappoint 8.125
ing 0.04803466796875
▁trial 0.58544921875
▁results 0.1376953125
▁would 2.8203125
▁be 1.26953125
▁a 0.121826171875
▁major 0.60205078125
▁set 0.48828125
back 0.00080108642578125
▁for 0.04718017578125
▁the 0.490234375
▁company 0.008392333984375
. 1.0419921875
<0x0A> 0.74072265625
<0x0A> 0.147216796875
Mar 3.53125
im 0.0030612945556640625
ast 0.0002930164337158203
at 0.0003783702850341797
' 1.5126953125
s 0.00033545494079589844
▁mechanism 2.98046875
▁of 0.0009531974792480469
▁action 0.0009484291076660156
▁as 6.890625
▁an 0.478515625
▁anti 0.923828125
- 0.001522064208984375
met 5.10546875
ast 0.6162109375
atic 0.302978515625
▁agent 0.87158203125
▁sets 4.2734375
▁it 0.004215240478515625
▁apart 0.0006794929504394531
▁from 0.0009946823120117188
▁most 3.994140625
▁other 0.1090087890625
▁cancer 0.75048828125
▁dru 0.1861572265625
gs 3.5762786865234375e-07
▁that 4.2890625
▁work 2.353515625
▁by 0.1171875
▁directly 1.5107421875
▁attack 2.31640625
ing 6.258487701416016e-05
▁tum 0.77783203125
or 0.165283203125
▁cells 0.005657196044921875
. 0.080078125
▁If 3.013671875
▁shown 4.91015625
▁effective 3.916015625
▁in 0.304931640625
▁st 2.337890625
om 0.00299835205078125
ach 2.2172927856445312e-05
▁cancer 0.01016998291015625
, 0.1617431640625
▁British 5.56640625
▁Bi 0.004329681396484375
ote 8.463859558105469e-06
ch 0.0003662109375
▁plans 1.24609375
▁to 0.0069122314453125
▁test 2.27734375
▁Mar 0.0740966796875
im 0.0017347335815429688
ast 0.0002467632293701172
at 0.0002760887145996094
▁in 0.044342041015625
▁additional 2.888671875
▁cancer 1.4384765625
▁types 0.8046875
▁including 2.0078125
▁col 2.294921875
ore 0.001697540283203125
ct 0.00026106834411621094
al 0.0004303455352783203
, 0.44775390625
▁breast 1.357421875
▁and 0.775390625
▁lung 0.70361328125
▁can 1.109375
cers 0.0001780986785888672
. 0.052734375
▁The 2.171875
▁company 0.3134765625
▁may 6.44921875
▁also 0.2171630859375
▁explore 2.234375
▁combinations 3.8203125
▁with 0.481201171875
▁other 0.1324462890625
▁ther 3.796875
ap 0.0010128021240234375
ies 0.00013256072998046875
▁like 4.390625
▁chem 1.7060546875
other 0.004177093505859375
apy 0.00669097900390625
, 2.2578125
▁target 2.359375
ed 0.005794525146484375
▁dru 2.0859375
gs 4.4345855712890625e-05
▁and 0.50048828125
▁imm 0.44482421875
un 0.07659912109375
other 0.005199432373046875
apy 0.73046875
. 0.373291015625
<0x0A> 0.396240234375
<0x0A> 0.12322998046875
The 2.3046875
▁medical 6.921875
▁community 0.529296875
▁is 0.951171875
▁eager 1.2431640625
▁to 1.4921875
▁see 1.1552734375
▁new 1.890625
▁treatment 2.3984375
▁options 0.0158233642578125
▁emer 4.58203125
ge 0.038238525390625
▁for 0.494873046875
▁st 0.978515625
om 6.103515625e-05
ach 2.7418136596679688e-06
▁cancer 0.0200042724609375
, 0.2144775390625
▁which 0.51220703125
▁is 1.1455078125
▁a 2.62109375
▁dead 2.248046875
ly 0.0006947517395019531
▁disease 0.307373046875
▁with 0.14208984375
▁few 1.943359375
▁effective 0.321533203125
▁treat 1.275390625
ments 2.372264862060547e-05
. 0.37109375
▁Pos 7.5390625
itive 0.00038170814514160156
▁late 7.78125
- 0.00878143310546875
stage 0.00662994384765625
▁trial 0.420166015625
▁results 0.1502685546875
▁would 2.044921875
▁put 3.61328125
▁British 1.3203125
▁Bi 0.0015964508056640625
ote 8.165836334228516e-05
ch 0.0001862049102783203
▁in 0.356201171875
▁a 0.33935546875
▁strong 0.2021484375
▁position 0.012451171875
▁to 0.0504150390625
▁gain 2.728515625
▁regul 0.751953125
atory 7.987022399902344e-05
▁appro 0.0031566619873046875
val 1.1324882507324219e-05
▁and 0.61572265625
▁market 1.6279296875
▁Mar 1.3623046875
im 0.0010023117065429688
ast 0.00047898292541503906
at 0.00014865398406982422
▁as 1.4130859375
▁early 6.43359375
▁as 0.0023860931396484375
▁next 1.041015625
▁year 0.001209259033203125
, 3.9296875
▁bringing 5.078125
▁hope 1.9296875
▁to 0.043426513671875
▁patients 0.5888671875
▁and 1.0654296875
▁profession 11.7890625
als 0.001522064208984375
▁fighting 5.90625
▁this 0.72412109375
▁difficult 1.8349609375
▁cancer 2.533203125
. 0.040496826171875
